Search Results

A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.

• Authors : Gao X; Sunshine Lake Pharma Co., Ltd., Dongguan, Guangdong, China.; Di Y

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/*analogs & derivatives; Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/administration & dosage ; Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/Immunoglobulin Fc Fragments*/adverse effects

• Source: Clinical and translational science [Clin Transl Sci] 2024 Apr; Vol. 17 (4), pp. e13775.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.

• Authors : Shi X; Department of Clinical Laboratory, Peking University First Hospital, Beijing, China .

Subjects: Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/adverse effects ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/therapeutic use ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage

• Source: BMJ case reports [BMJ Case Rep] 2024 May 06; Vol. 17 (5). Date of Electronic Publication: 2024 May 06.Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X

Record details

A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies.

• Authors : Tipa RO; Department of Psychiatry, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; 'Prof. Dr. Alexandru Obregia' Clinical Psychiatric Hospital, 041914 Bucharest, Romania.

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/pharmacology ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Cognition*/Cognition*/Cognition*/drug effects

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 02; Vol. 25 (9). Date of Electronic Publication: 2024 May 02.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.

• Authors : Evans M; Diabetes Resource Centre, University Hospital Llandough, Penlan Road, Llandough, Cardiff, CF64 2XX, UK. .; Husain M

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use

• Source: Advances in therapy [Adv Ther] 2024 May; Vol. 41 (5), pp. 1843-1859. Date of Electronic Publication: 2024 Feb 10.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.

• Authors : Ghusn W; Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.; Fansa S

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Weight Loss*/Weight Loss*/Weight Loss*/drug effects

• Source: International journal of obesity (2005) [Int J Obes (Lond)] 2024 May; Vol. 48 (5), pp. 662-667. Date of Electronic Publication: 2024 Feb 01.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101256108 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

A new indication for semaglutide (Wegovy).

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/adverse effects ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

• Source: The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2024 Apr 29; Vol. 66 (1701), pp. 66-67.Publisher: The Medical Letter Country of Publication: United States NLM ID: 2985240R Publication Model: Print Cited Medium: Internet ISSN:

Record details

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

• Authors : Butler J; STEP-HFpEF Trial Committees and Investigators

Subjects: Heart Failure*/Heart Failure*/Heart Failure*/drug therapy ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

• Source: Lancet (London, England) [Lancet] 2024 Apr 27; Vol. 403 (10437), pp. 1635-1648. Date of Electronic Publication: 2024 Apr 07.Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X

Record details

Semaglutid kan være aktuelt for mange.

• Authors : Lee-Ødegård S; Valderhaug T; Myhre PL

Subjects: Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/adverse effects ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use

• Source: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke [Tidsskr Nor Laegeforen] 2024 Apr 26; Vol. 144. Date of Electronic Publication: 2024 Apr 26 Publisher: Norske Laegeforening Country of Publication: Norway NLM ID: 0413423 Publication Model: Electronic-Print Cited Medium: Internet ISSN:

Record details

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

• Authors : Kosiborod MN; STEP-HFpEF DM Trial Committees and Investigators

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/etiology ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/administration & dosage

• Source: The New England journal of medicine [N Engl J Med] 2024 Apr 18; Vol. 390 (15), pp. 1394-1407. Date of Electronic Publication: 2024 Apr 06.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium:

Record details

Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.

• Authors : Feier CVI; First Discipline of Surgery, Department X-Surgery, 'Victor Babes' University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania.; First Surgery Clinic, 'Pius Brinzeu' Clinical Emergency Hospital, 300723 Timisoara, Romania.

Subjects: Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/therapeutic use ; Glucagon-Like Peptides*/Glucagon-Like Peptides*/Glucagon-Like Peptides*/adverse effects

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 15; Vol. 25 (8). Date of Electronic Publication: 2024 Apr 15.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details